A pilot study of proton beam theary for mucosal melanoma of the head and neck

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. e17042-e17042
Author(s):  
S. Zenda ◽  
M. Kawashima ◽  
R. Kohno ◽  
S. Arahira ◽  
T. Nishio ◽  
...  
Keyword(s):  
Head And Neck ◽  
Proton Beam ◽  
Proton Therapy ◽  
Progression Free Survival ◽  
Late Toxicity ◽  
Distant Metastases ◽  
Proton Beam Therapy ◽  
Mucosal Melanoma ◽  
Cervical Lymph Nodes ◽  
Number Of Patients

e17042 Background: The aim of this study is to clarify the clinical profile of proton beam therapy for mucosal melanoma of the head and neck. Methods: Patients with mucosal melanoma of the head and neck fulfilling the following criteria were enrolled: histologically confirmed malignant melanoma; N0 and M0 disease. Proton therapy was delivered three times a week with planned total dose of 60 GyE in 15 fractions. Results: From January 2004 through January 2007, thirteen patients were enrolled in this study. Patients’ characteristics were as follows: median age, 75 years (range, 56 to 79); male/female, 7/6; T1/2/3/4/rec, 3/2/0/7/1. All could receive the full dose of proton therapy. The most common acute toxicities were mucositis (grade 3: 15%) and dermatitis (grade 2: 15%). One patient had unilateral impairment of visual acuity possibly related with treatment. Initial local control rate was 77.0% (10/13, 95%CI: 46.2–95.0%). With median follow up period of 33.7 months, median progression free survival was 18.9 months and median survival time was not reached. 2-year overall survival rate was 69.7% (95%CI: 31.6–86.1%). Most frequent site of first failure was cervical lymph nodes outside of PTV. Four patients died of disease; cachexia caused by distant metastases in three and carotid blowout because of nodal disease in one. Conclusions: Proton beam therapy for mucosal melanoma of the head and neck achieved favorable results in this limited number of patients, although further investigation about late toxicity is needed. Now, the phase II study of this treatment is ongoing. No significant financial relationships to disclose.

Proton Beam Therapy as a Nonsurgical Approach to Mucosal Melanoma of the Head and Neck: A Pilot Study

2011 ◽  
Vol 81 (1) ◽  
pp. 135-139 ◽  
Author(s):  
Sadamoto Zenda ◽  
Mitsuhiko Kawashima ◽  
Teiji Nishio ◽  
Ryosuke Kohno ◽  
Keiji Nihei ◽  
...  
Keyword(s):  
Pilot Study ◽  
Head And Neck ◽  
Proton Beam ◽  
Proton Beam Therapy ◽  
Mucosal Melanoma

scholarly journals Proton Therapy for Major Salivary Gland Cancer: Clinical Outcomes

2021 ◽  
Vol 8 (1) ◽  
pp. 261-272
Author(s):  
Alexander N. Hanania ◽  
Xiaodong Zhang ◽  
G. Brandon Gunn ◽  
David I. Rosenthal ◽  
Adam S. Garden ◽  
...  
Keyword(s):  
Overall Survival ◽  
Salivary Gland ◽  
Proton Beam ◽  
Local Control ◽  
Proton Therapy ◽  
Late Toxicity ◽  
Proton Beam Therapy ◽  
Major Salivary Gland ◽  
Grade 3

Abstract Purpose To report clinical outcomes in terms of disease control and toxicity in patients with major salivary gland cancers (SGCs) treated with proton beam therapy. Materials and Methods Clinical and dosimetric characteristics of patients with SGCs treated from August 2011 to February 2020 on an observational, prospective, single-institution protocol were abstracted. Local control and overall survival were calculated by the Kaplan-Meier method. During radiation, weekly assessments of toxicity were obtained, and for patients with ≥ 90 days of follow-up, late toxicity was assessed. Results Seventy-two patients were identified. Median age was 54 years (range, 23-87 years). Sixty-three patients (88%) received postoperative therapy, and nine patients (12%) were treated definitively. Twenty-six patients (36%) received concurrent chemotherapy. Nine patients (12%) had received prior radiation. All (99%) but one patient received unilateral treatment with a median dose of 64 GyRBE (relative biological effectiveness) (interquartile range [IQR], 60-66), and 53 patients (74%) received intensity-modulated proton therapy with either single-field or multifield optimization. The median follow-up time was 30 months. Two-year local control and overall survival rates were 96% (95% confidence interval [CI] 85%-99%) and 89% (95% CI 76%-95%], respectively. Radiation dermatitis was the predominant grade-3 toxicity (seen in 21% [n = 15] of the patients), and grade ≥ 2 mucositis was rare (14%; n = 10 patients). No late-grade ≥ 3 toxicities were reported. Conclusion Proton beam therapy for treatment of major SGCs manifests in low rates of acute mucosal toxicity. In addition, the current data suggest a high rate of local control and minimal late toxicity.

Nasopharyngeal carcinoma with secondaries at the porta hepatis presenting as obstructive jaundice

1990 ◽  
Vol 104 (1) ◽  
pp. 41-42 ◽  
Author(s):  
S. Elango ◽  
C. R. Jayakumar
Keyword(s):  
Head And Neck Cancer ◽  
Nasopharyngeal Carcinoma ◽  
Obstructive Jaundice ◽  
Lymph Nodes ◽  
Head And Neck ◽  
Nasopharyngeal Cancer ◽  
Distant Metastases ◽  
Porta Hepatis ◽  
Cervical Lymph Nodes ◽  
The Common

AbstractRecent reports have dispelled the previously held concept that head and neck cancer rarely metastases beyond the cervical lymph nodes. Nasopharyngeal cancer has been reported to have a higher incidence of distant metastases compared to other head and neck cancers, the common sites being bone, lung and liver. A case of nasopharyngeal carcinoma presenting as obstructive jaundice because of secondaries at the porta hepatis is presented here.

scholarly journals Impact of robust treatment planning on single- and multi-field optimized plans for proton beam therapy of unilateral head and neck target volumes

2017 ◽  
Vol 12 (1) ◽  
Author(s):  
Macarena Cubillos-Mesías ◽  
Michael Baumann ◽  
Esther G. C. Troost ◽  
Fabian Lohaus ◽  
Steffen Löck ◽  
...  
Keyword(s):  
Head And Neck ◽  
Treatment Planning ◽  
Proton Beam ◽  
Proton Beam Therapy ◽  
Target Volumes

Proton Beam Therapy for Locally Advanced Head and Neck Tumors

2021 ◽  
Vol Publish Ahead of Print ◽  
Author(s):  
Saad Sheikh ◽  
Michael Z. Kharouta ◽  
Rajesh Pidikiti ◽  
Nicholas J. Damico ◽  
Serah Choi ◽  
...  
Keyword(s):  
Head And Neck ◽  
Proton Beam ◽  
Locally Advanced ◽  
Proton Beam Therapy ◽  
Head And Neck Tumors ◽  
Advanced Head ◽  
Neck Tumors

scholarly journals Salvage radiotherapy for second oligo-recurrence in patients with breast cancer

2017 ◽  
Vol 59 (1) ◽  
pp. 58-66 ◽  
Author(s):  
Mari Miyata ◽  
Takayuki Ohguri ◽  
Katsuya Yahara ◽  
Shinsaku Yamaguchi ◽  
Hajime Imada ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Objective Response ◽  
Local Therapy ◽  
Progression Free Survival ◽  
Late Toxicity ◽  
Distant Metastases ◽  
Salvage Radiotherapy ◽  
Severe Toxicity ◽  
Term Survival ◽  
Grade 3

Abstract A new concept designated ‘oligo-recurrence (OR)’ has been proposed, which indicates one to several distant metastases/recurrences in one or more organs, which can be treated with local therapy, after the primary site of the cancer has been controlled. The purpose of this study was to assess the efficacy and toxicity of salvage radiotherapy (RT) for the second OR of breast cancer. The second OR was defined as once-salvaged patients with OR who had a second failure that was also detected as the state of OR. Twenty-one patients with second OR were treated with salvage RT and were retrospectively analyzed. The sites of the second OR were locoregional recurrence in 7 patients and distant metastasis in 14 patients. Salvage RT was performed at a median total dose of 60 Gy. Nineteen (90%) patients had an objective response. The median overall survival and progression-free survival (PFS) times were 41 and 24 months after salvage RT for the second OR, respectively. The 3-year local (in-field) control (LC) rates were 93%. The toxicities were mild; acute toxicities ≥Grade 3 were seen in one patient with Grade 3 dermatitis, and no late toxicity ≥Grade 2 was observed. In conclusion, salvage RT for the second OR was able to achieve a better LC rate and longer PFS time without inducing severe toxicity, and therefore may be a potentially effective modality for inducing long-term survival in select patients.

SU-E-T-491: A FLUKA Monte Carlo Computational Model of a Scanning Proton Beam Therapy Nozzle at IU Proton Therapy Center

2012 ◽  
Vol 39 (6Part17) ◽  
pp. 3818-3818 ◽  
Author(s):  
V Moskvin ◽  
C Cheng ◽  
V Anferov ◽  
D Nichiporov ◽  
Q Zhao ◽  
...  
Keyword(s):  
Monte Carlo ◽  
Computational Model ◽  
Proton Beam ◽  
Proton Therapy ◽  
Proton Beam Therapy ◽  
Therapy Center

Multi-centre prospective assessment of accuracy and impact on management of positron emission tomography (PET) in esophageal and gastroesophageal junction cancers (EC). Australian PET Data Collection Project

2007 ◽  
Vol 25 (18_suppl) ◽  
pp. 4534-4534 ◽  
Author(s):  
B. E. Chatterton ◽  
I. Ho-Shon ◽  
N. Lenzo ◽  
A. Patrikeos ◽  
B. Kelley ◽  
...  
Keyword(s):  
Imaging Techniques ◽  
Gastroesophageal Junction ◽  
Standardized Uptake Value ◽  
Progression Free Survival ◽  
Distant Metastases ◽  
Regional Lymph Nodes ◽  
Palliative Intent ◽  
Positron Emission ◽  
Regional Metastases ◽  
Number Of Patients

4534 Background: In localized EC, radical surgery may be curative. This study evaluated PET and conventional imaging techniques (CI) for staging, and the potential impact of PET on management and prognosis of EC. Methods: Subjects had confirmed EC (SCC or adenocarcinoma), were fit for investigation and surgery and/or chemoradiotherapy and had no unequivocal distant metastatic disease clinically or by CT and endoscopy at presentation. Sensitivity, including N and M staging of pre-operative CT, PET and endoscopic ultrasound (EUS) and clinical impact of confirmation or detection of metastases on intent (curative or palliative) were recorded. Management changes, including radiotherapy field determined by new information from PET, were recorded. Variables, including standardized uptake value (SUV) were compared with progression-free survival (PFS.) Results: 129 patients (104 male), mean age 66 (range 36- 87) were evaluated. 127 of 129 primary lesions were detected. In 41% of patients, PET detected a total of 148 additional lesions, 75 regional lymph nodes, 72 distant metastases and 1 second EC primary. 22% of patients were upstaged from M0 to M1. CT detected regional and distant metastases in 57% and 0% (entry criterion), PET in 70% and 44%. Of 20 patients who had EUS, it detected regional metastases in 67%, PET in 33%.The number of patients intended to be treated palliatively increased from 10 pre- to 32 post-PET. Of patients with curative management intent based on PET 34% progressed in 12 months, with palliative intent 59%. Significant changes in management (high or medium impact) occurred in 38%. The PFS of 54 patients below and 54 above the median SUV(8) was no different (p=0.79) Conclusions: PET influenced management in 38% of patients with EC already studied by CI. No significant financial relationships to disclose.

Sign in / Sign up

Export Citation Format

Share Document